Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026)
Coherus Oncology (CHRS) posted Interest Coverage Ratio of 16.54 for Q1 2026, down 185.8% sequentially from 5.79 in Q4 2025, and down 218.99% YoY from 13.9 in Q1 2025.
Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Interest Coverage Ratio for 14 years, with the latest figure at 16.54 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 218.99% year-over-year to 16.54 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.88 (up 56.13% YoY) and the FY2025 annual result came in at 0.49, down 1.74% from the prior year.
- Interest Coverage Ratio retreated to 16.54 in Q1 2026 per CHRS's latest filing, from 5.79 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 1.72 in Q4 2022 and troughed at 21.74 in Q1 2024.
- A 5-year average of 9.61 and a median of 7.07 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio sank 431.73% in 2024, then surged 76.15% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 1.72 in 2022, then tumbled by 276.61% to 6.49 in 2023, then retreated by 8.96% to 7.07 in 2024, then advanced by 18.16% to 5.79 in 2025, then sank by 185.8% to 16.54 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 16.54, 5.79, and 16.64 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -13.92 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.92 |
| Mar 31, 2026 | -16.54 |
| Dec 31, 2025 | -5.79 |
| Sep 30, 2025 | -16.64 |
| Jun 30, 2025 | -15.98 |
| Mar 31, 2025 | -5.18 |
| Dec 31, 2024 | -7.07 |
| Sep 30, 2024 | -16.57 |
| Jun 30, 2024 | -9.76 |
| Mar 31, 2024 | -21.74 |
| Dec 31, 2023 | -6.49 |
| Sep 30, 2023 | -3.12 |
| Jun 30, 2023 | -3.47 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -1.72 |
| Sep 30, 2022 | -10.67 |
| Jun 30, 2022 | -6.69 |
| Mar 31, 2022 | -9.02 |
| Dec 31, 2021 | -6.83 |
| Sep 30, 2021 | -5.46 |